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Background: Gastrointestinal reflux disease (GERD) is a common disorder that negatively impacts health-related
quality of life (HRQL) and work productivity. Many patients have only a partial response to proton pump inhibitor
(PPI) therapy and continue to experience GERD symptoms despite optimized treatment. This observational study
aimed to provide information on symptoms, HRQL, resource usage, costs and treatment pathways associated with
partial response to PPI therapy in French patients with GERD.
Methods: Patients with partial response to PPI therapy, defined as persistent GERD symptoms ≥3 days/week
despite optimized treatment with a PPI, were recruited for this 12-month observational study. GERD symptoms,
HRQL, work productivity and resource use were assessed by patient surveys. Costs were calculated based on lost
work productivity and resource use.
Results: The patient population (n=262; mean age, 54 years; 40% men) carried a significant symptom burden, with
98% of patients having moderate-to-severe GERD symptoms and 65% of patients experiencing daily symptoms at
baseline. HRQL and work productivity were significantly impaired, with a greater degree of impairment in patients
with higher symptom burden. The mean total cost per patient over the 12-month follow-up period was €5237, of
which €4674 (89%) was due to lost work productivity.
Conclusions: Partial response to PPI therapy for GERD is associated with a high symptom burden, significant
impairment of HRQL and work productivity, and substantial GERD-related costs.
Keywords: PPIs, GERD, Quality of life, ProductivityBackground
Gastroesophageal reflux disease (GERD) is a common
disorder, the predominant symptoms of heartburn and/
or regurgitation affecting approximately 10–20% of the
adult population in the Western world [1]. A national
survey showed that the prevalence of GERD in France is
at the lower end of this scale, with approximately 10% of
the adult population affected by at least one typical* Correspondence: stanislas.bruleydesvarannes@chu-nantes.fr
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The survey also noted that GERD symptoms occurred
daily in about 15% of patients, and at least once weekly
in 73%, with negative impact on health-related quality of
life (HRQL). Such impact was most pronounced in
patients with higher symptom frequency, extra-digestive
symptoms and endoscopic lesions of greater severity.
Treatment with a proton pump inhibitor (PPI) is gene-
rally effective for the treatment of GERD [3]. However,
17–32% of patients have only a partial response and con-
tinue to experience GERD symptoms despite optimized
therapy with a PPI [4]. Indeed, a study of partial response
to PPI treatment in the USA confirmed the burden ofentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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experienced an approximate 30% reduction in work prod-
uctivity, and a 41% reduction in productivity during daily
activities, with the degree of productivity and HRQL im-
pairment being positively correlated with the severity and
frequency of GERD symptoms despite optimized PPI ther-
apy [5]. Currently, however, there are little data on disease
burden, resource use, costs and treatment pathways in this
patient population in Europe.
The REMAIN (Partial Response to PPI treatment: the
Cost to Society and the Burden to the Patient) France
study therefore aimed to provide information on the treat-
ment pathways, resource utilization, costs, symptoms and
HRQL in European patients with GERD who were newly
identified as partial responders to optimized PPI therapy.Methods
Study design and patients
REMAIN France was a 12-month multicenter, non-
interventional, observation study conducted at 50 pri-
mary and secondary care sites in France (NCT00842855;
AstraZeneca study code: D9120N00013). Participating
sites comprised primary care (n=24) and specialist
(gastroenterologist) centers (n=26). The study enrolled
patients aged 18 years or older with a diagnosis of GERD
(established ≥6 months previously) who were newly iden-
tified as partial responders to optimized PPI therapy dur-
ing regular physician visits (pre-arranged appointments
were not set up for patients to be screened for enroll-
ment). Partial response was defined pragmatically as
GERD symptoms despite optimized PPI therapy,
according to the physician’s judgement. In this regard,
physicians were asked to record the reason why PPI ther-
apy was considered optimized, including ‘maximum dose’
(physicians were not provided with guidance in terms of
what constituted ‘maximum’ dose), ‘tried different brands
with no improvement’, ‘improvement by changing PPI un-
likely due to symptom pattern’ and ‘other reason’ (multiple
responses possible). In addition, patients had to report ≥3
days/week of a burning feeling behind the breastbone
(‘heartburn’) of at least moderate intensity and/or ≥3 days/
week of an unpleasant movement of material upwards
from the stomach (‘regurgitation’) of at least moderate in-
tensity, as determined by the validated Reflux Symptom
Questionnaire 7-day recall (RESQ-7) [6].
Patients who had not experienced any GERD symptom
improvement during PPI therapy, who had prior surgery
of the upper gastrointestinal tract or had any condition
that would render the patient unsuitable for inclusion in
the study, were excluded.
Written informed consent was obtained from all enrolled
patients, who were not remunerated for their participation.
Physicians received compensation for their involvement inthe study. The study protocol was approved by the Com-
mission Nationale Informatique et Liberté (CNIL).
Patient-reported outcomes
Patient-reported outcomes were evaluated in terms of
GERD-specific symptoms, HRQL and work productivity
during follow-up, as described below. Paper-based
forms/surveys were used, and considerable steps were
taken to ensure their completeness as part of usual study
monitoring. Indeed, patient surveys were completed in
the physician office, which allowed for reminders to be
made if information was incomplete.
Symptoms
GERD-specific symptoms were evaluated at baseline and at
3, 6, 9 and 12 months’ follow-up using RESQ-7 [6], a
patient-reported outcome instrument based on the Reflux
Disease Questionnaire [7]. The RESQ-7 is self-administered
questionnaire that uses 26 questions to assess the frequency
and intensity of GERD symptoms over the past 7 days.
Symptoms are rated on a 6-point Likert scale, with higher
scores indicating more frequency or intense symptoms. The
individual symptom items can be combined into an Overall
symptoms domain and four separate domains comprising:
Heartburn; Regurgitation; Hoarseness, cough and difficulty
swallowing; and the single item Burping.
Depression and anxiety were assessed on the Hospital
Anxiety and Depression Scale (HADS) [8] at baseline
and 12 months’ follow-up. The HADS is a 14-item self-
assessment scale, with each item scored on a four point
response category (0–3). The scale produces an anxiety
score and a depression score (0–7, no disorder; 8–10,
‘possible’ anxiety or depression; ≥11, ‘probable’ anxiety or
depression).
Health-related quality of life
HRQL was assessed at baseline and at 6 and 12 months’
follow-up using the 36-item Short-Form Health Survey
(version 2 acute, SF-36v2) with a 7-day recall period [9]
and the European Quality of Life-5 Dimensions (EQ-5D)
[10]. SF-36v2 is a generic quality-of-life instrument that
assesses physical functioning, bodily functioning and role
limitations due to health problems, role limitations due
to personal or emotional problems, emotional well-
being, social functioning, energy/fatigue, general health
problems and perceived change in health. It yields an
eight-scale profile of functional health and well-being
scores as well as Physical and Mental Component sum-
mary scores (0–100), with higher scores indicating a
more favorable health state.
The EQ-5D is a health-outcome measure that provides
a descriptive profile and an index score for health status.
The index score is based on five questions covering
aspects of health (mobility, self-care, usual activities,
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levels (no problems, some/moderate problems and ex-
treme problems). In addition, another measure of health
status is assessed on a vertical graduated visual analog
scale. The index and VAS scores are both presented as
values between 0 and 1, where 0 represents a health
state of being dead and 1 represents a health state of
being at full health.
Work productivity
Work productivity was assessed using the Work Productiv-
ity and Activity Impairment-GERD (WPAI-GERD) ques-
tionnaire [11] at baseline and at 3, 6, 9 and 12 months’
follow-up. The WPAI-GERD consists of six questions, and
assesses GERD-related impairment of work productivity
and activity over the past 7 days. The questionnaire yields a
number of scores, such as: absenteeism (hours of work
time missed; employed patients); presenteeism (impairment
at work/reduced on-the-job effectiveness; employed
patients); and activity impairment because of GERD
(employed and non-working patients). Presenteeism and
activity impairment outcomes are expressed as
percentages, with higher percentages indicating greater
impairment and less productivity. The number of work
hours lost due to presenteeism is calculated by multiplying
the percentage reduced productivity while at work by the
number of hours the responder actually worked.
GERD-related resource utilization and costs
Resource utilization specific to GERD was evaluated in
terms of medication use, medical consultations, emergency
room visits, hospitalizations and tests and procedures during
the study. As part of retrospective data collection, physicians
noted which medications considered to be relevant for pa-
tient care were prescribed during the 6 months before base-
line, along with tests and procedures that were performed.
For the 12-month follow-up phase of the study, patients
self-reported on prescribed GERD and over-the-counter
(OTC) medications, including treatment duration for each
therapy. Such information was used to describe common
treatment pathways for the patient population during the
course of the study.
Medical consultations, emergency room visits and
hospitalizations during the study were reported by
physicians and patients by means of case report forms
(CRFs) and survey forms, respectively. In cases where the
number of primary care physician/specialist visits reported
by patients was inconsistent with the number of visits
reported by physicians, the maximum number of visits
(between patient- and physician-reported information)
was used. The justification for taking this approach, when
the physician reported a higher number of visits, was that
the patient had probably forgotten to report some of the
visits. Conversely, the number of visits reported bypatients was sometimes higher as the patient could visit
other physicians than the study investigator.
Medication costs were derived from the Caisse Nationale
d’Assurance Maladie des Travailleurs Salariés (CNAMTS)
using basic medicines and pricing information [12]. Costs
of non-reimbursed medications were obtained directly
from a pharmacist. Prescribed and OTC medications were
included in the total direct cost calculation, as this analysis
was performed using the societal perspective.
Medical consultation costs were obtained from CNA-
MTS using conventional tariffs for the public sector
[13], and from the Ecosanté France database for the pri-
vate sector [14]. The unit cost used was a weighted aver-
age of the two sectors according to proportions reported
in 2006 [15]. Charges for diagnostic procedures were
also obtained from the CNAMTS according to the Clas-
sification Commune des Actes Médicaux (CCAM).
The cost of productivity loss was calculated using a mean
hourly labor cost of €31.97, obtained from the labor costs
section in the Eurostat website [16]. The number of hours
absent from work and number of hours lost due to reduced
work productivity over the past 7 days were calculated using
the WPAI-GERD results. The number of hours collected at
baseline was applied for the 6-month period prior to base-
line. Similarly, the number of hours at 3 months was applied
for the period between baseline and 3 months, the number
of hours at 6 months was applied for the period between
3 months and 6 months, the number of hours at 9 months
was applied for the period between 6 months and 9 months,
and the number of hours at 12 months was applied for the
period between 9 months and 12 months. Productivity loss
was adjusted to reflect the total study population when cal-
culating productivity costs per patient.
Statistical analyses
All statistical analyses were descriptive, due to the
objectives of the study. Consequently, there are no hy-
potheses to test with statistical methods to predetermine
a required sample size. The protocol specified a target
enrollment of 275 patients with GERD and partial re-
sponse to optimized PPI treatment. Assuming an attri-
tion rate of 30% over the course of the study, the final
sample size would be approximately 200 patients for
analysis. This sample size was pragmatic and deemed
sufficient given the descriptive objectives of the study.
95% confidence intervals (CIs) were used to visualize the
variability of estimates, and were based on normal distri-
bution approximations. No adjustments were made to
account for missing data.
Results
Patient characteristics
A total of 273 patients were screened for inclusion in the
study, of which 264 patients met the inclusion criteria. At
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262 patients, and 260 patients completed the patient sur-
vey. Four patients dropped out over the course of the
study, with CRFs and patient surveys completed for 258
patients and 226 patients, respectively, at the 12-month
follow-up visit. The flow of patients through the study is
depicted in Figure 1.
The mean age of the study population was 54 years,
40% of patients were men and the mean body mass
index was 26.6 kg/m2. A total of 49% of patients were
employed (2% were on sick leave), 15% were un-
employed and the remaining 36% of patients were
retired. On the HADS scale, 21.5% of patients were clas-
sified as having probable anxiety and 13% were classified
as having probable depression.
The reasons for considering PPI therapy to be optimized
were recorded by physicians (multiple response possible);
the ‘maximum dose’ had been reached in 86% of patients,
46% of patients had tried a different brand with no im-
provement, improvement by changing PPI was consideredFigure 1 Flow of patients through the REMAIN France study and follounlikely due to symptom pattern in 29% and PPI therapy
was considered optimized due to other reasons in 9% of
patients. Data on use of OTC drugs were not gathered
prior to the baseline visit.
A total of 54% and 33% of patients, respectively, had a
history of dyspeptic symptoms and reflux (erosive)
esophagitis at baseline. Mean duration of GERD
symptoms was 7.8 years. Some 76% of patients had
undergone upper gastrointestinal endoscopy within
6 months prior to baseline, with findings reported in
74% of patients. Baseline clinical characteristics are
presented in Table 1.
GERD-related resource utilization
Use of prescribed GERD medication generally remained
constant over the 12-month study period. Esomeprazole
was the most commonly prescribed GERD medication,
with use reported in 46% of patients between baseline
and 12 months (Table 2). Between baseline and
6 months, the most common test or procedure wasw-up process.
Table 2 Use of GERD medications between baseline and











Other drugs for peptic ulcer and GERD 79 (31)
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common procedures between 6 and 12 months were
blood sampling for laboratory tests (6% of patients) and
endoscopy (4%). Over the 12-month study period, pri-
mary care physician visits were reported for 32% and
74% of patients on CRF forms and patient surveys, re-
spectively, while gastroenterologist visits were reported
for 19% and 35% of patients, respectively. A total of
6 patients (2%) were reported as being hospitalized dur-
ing the study.
Symptom burden, HRQL and productivity impairment
At baseline, GERD symptoms (reported using the RESQ-7,
Overall symptoms domain) were reported as moderate-to
-severe in 98% of patients. Patients’ most frequent symp-
tom from the Heartburn and Regurgitation domains were
frequently reported as moderate-to-severe in intensity
(95% and 79%, respectively), while patients’ most frequent
symptoms from the Burping and Hoarseness, cough and
difficulty swallowing domains were rated as moderate-to
-severe in 53% and 35% of patients, respectively. A total of
48% of patients reported daily symptoms of GERD despite
optimized PPI therapy. The frequency and severity of
GERD symptoms appeared to decline over the 12-month
course of the study (data not shown).
SF-36v2 and EQ-5D scores at baseline and at 6 and
12 months’ follow-up are shown in Table 3. SF-36v2 Phys-
ical and Mental Component summary scores, EQ-5D
index score and EQ-5D VAS score all showed a tendency
towards lower scores (worse HRQL) with a higher
frequency and intensity of GERD symptoms (Figures 2
and 3).
WPAI-GERD results at baseline showed that the mean
time absent from work in the previous 7 days due to
GERD was 2.9 hours (95% CI: 1.18, 4.56; n=99) perTable 1 Clinical characteristics from 6 months prior to
baseline to baseline visit
Variable n=262 (%)
Gastrointestinal history
Dyspeptic symptoms 141 (54)
Hiatal hernia 103 (39)
Reflux esophagitis 86 (33)
Endoscopic findings*
Hiatal hernia 84 (32)
Reflux esophagitis 50 (19)
Barrett’s esophagus 16 (6)
Esophageal stricture 3 (1)
Duodenal ulcer 2 (0.8)
Other abnormal esophageal findings 28 (11)
* 11.5% of patients underwent upper gastrointestinal endoscopy with biopsy
and 21% underwent the procedure without biopsy; an additional 44% of
patients had the procedure without further details specified.employed patient, and mean productivity loss while at
work was 23.4% (95% CI: 19.2%, 27.5%), corresponding
to an average of 7.7 hours (95% CI: 6.2, 9.1; n=101) of
work lost due to reduced productivity. Thus, the overall
productivity loss was estimated as 10.1 hours (95% CI:
7.9, 12.3) per employed patient. Mean percentage reduc-
tion in productivity while carrying out daily activities
(for employed and non-working patients) was 34.4%
(95% CI: 31.3%, 37.5%; n=236). All WPAI-GERD domain
scores appeared to worsen as the frequency and severity
of GERD symptoms increased (data not shown).
Treatment pathways
Over time, the most common treatment pathway was that
patients remained on PPI monotherapy. At month 12 of
follow-up (n=258), around one third of patients (33.7%)
were receiving PPI monotherapy and a small proportion
(8.5%) were receiving adjunctive agents (most commonly
alginates or domperidone) or other medication (0.8%).
The remainder were receiving no medication at this
timepoint. Notably, the proportion of patients receiving
no medical therapy increased over time (from 20.2% of
patients during months 1–6 of follow-up to 57.0% at
month 12).
Costs
In the 6 months prior to baseline, the mean total cost
per patient was €3726, of which €361 (10%) was direct
costs and €3365 (90%) was indirect costs due to absence
from work and reduced productivity. Over the 12-month
follow-up period, the mean total cost per patient was
€5237, of which €563 (11%) was direct costs and €4674
(89%) was indirect costs. Total costs per patient are
presented in Table 4.
Discussion
This non-interventional, observation study shows that
there is a high symptom load and substantial impairment
Table 3 Mean (95% CI) SF-36v2 Physical and Mental Component summary scores and EQ-5D index and VAS scores at
baseline and at 6 and 12 months’ follow-up
Baseline 6 months 12 months
(n=262) (n=260) (n=258)
SF-36v2
Physical Component 45.0 (43.9, 46.0) 46.7 (45.6, 47.9) 46.9 (45.7, 48.1)
n=231 n=202 n=210
Mental Component 41.1 (39.6, 42.6) 42.6 (41.1, 44.2) 42.6 (41.0, 44.2)
n=231 n=201 n=211
EQ-5D
Index score 0.68 (0.65, 0.71) 0.70 (0.66, 0.73) 0.72 (0.69, 0.75)
n=236 n=212 n=212
VAS* 0.64 (0.61, 0.66) 0.68 (0.65, 0.70) 0.67 (0.65, 0.70)
n=234 n=211 n=215
* Scores were re-scaled from 0–100 to 0–1 for purposes of comparison.
Figure 2 Mean SF-36v2 Physical and Mental Component summary scores by RESQ-7 Heartburn domain frequency (a) and severity (b)
at 6 months’ follow-up. For both scores, 0 represents worse and 100 represents best health status. Norm values are means derived from the
1998 SF-36 Health Survey of the US general population. Frequency and severity of symptoms were based on the item within the domain with
the highest frequency. The relationship between symptoms and SF-36v2 results is described at the 6-month assessment, since the number of patients
in each symptom category was most evenly distributed at this time point.
Bruley des Varannes et al. BMC Gastroenterology 2013, 13:39 Page 6 of 10
http://www.biomedcentral.com/1471-230X/13/39
Figure 3 Mean EQ-5D index and VAS scores by RESQ-7 Heartburn domain frequency (a) and severity (b) at 6 months’ follow-up. For
both EQ-5D scores, 0 represents a health state of being dead and 1 a health state of being at full health (VAS scores were re-scaled from 0–100
to 0–1 for purposes of comparison). Frequency and severity of symptoms were based on the item within the domain with the highest frequency.
The relationship between symptoms and EQ-5D results is described at the 6-month assessment, since the number of patients in each symptom
category was most evenly distributed at this time point.
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with persistent symptoms of GERD despite optimized PPI
therapy, with 98% of patients reporting moderate-to-severe
symptoms and 48% reporting daily symptoms at baseline.
This symptom burden was consistent with the study inclu-
sion criteria of patients with GERD symptoms at least
3 days/week despite optimized PPI therapy.
The symptom burden in the study population appeared
to decrease over the 12-month course of the study. This
was expected, as the patients had a high symptom load at
recruitment and GERD symptoms tend to fluctuate over
time [17,18]. Another possible explanation is increased pa-
tient compliance with prescribed PPI therapy as a result of
being enrolled in this study. It is important to note, how-
ever, that the REMAIN France study was not designed toevaluate changes in symptoms over time (or GERD treat-
ment compliance), and therefore comparisons between
baseline and follow-up should be interpreted with caution.
In addition to the high symptom load, the study popu-
lation was found to have impaired HRQL as assessed by
the EQ-5D and SF-36v2 scales, with the level of impair-
ment being higher in patient categories with more
frequent and/or severe symptoms. This finding was con-
sistent with observations from several studies that
assessed HRQL in patients with GERD using the EQ-5D
and SF-36 instruments. For example, Kartman et al. [19]
surveyed 1011 patients with GERD in Sweden and
Germany, assessing HRQL on the EQ-5D, as well as the
frequency and severity of heartburn. The study found
that patients with heartburn assign themselves an
Table 4 Mean (95% CI) total costs per patient for
6 months prior to baseline and months 1–12




Total costs 3726 (2876, 4575) 5237 (3949, 6526)
Total direct costs* 361 (327, 394) 563 (503, 623)
Primary care visits** 99 (86, 112)
Specialist visits** 45 (36, 54)
Emergency room visits** 0.14 (-0.13, 0.41)
Hospitalisations** 25 (-4, 55)
Medication 203 (184, 222) 351 (314, 389)
Tests and procedures 157 (129, 186) 42 (20, 64)
Total work productivity
loss cost
3365 (2515, 4216) 4674 (3385, 5964)
Cost of absence from work 906 (360, 1452) 799 (232, 1366)
Cost of reduced productivity
at work
2460 (1860, 3060) 3875 (2854, 4897)
* Total direct costs include only costs of tests and procedures and costs of
GERD-related prescribed medications; ** This information was not collected in
the 6-month period prior to baseline.
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between utility impairment and the severity and fre-
quency of their symptoms.
A number of studies have assessed the impact of
GERD on HRQL using the SF-36v1 [20-25], with all
studies showing a significant impairment of quality of
life in patients with GERD compared with the general
population, both on the Physical and Mental Compo-
nent summary scores and the individual domains of the
SF-36v1. As with the EQ-5D, the degree of impairment
of HRQL as assessed on the SF-36v1 was related to
symptom load, with HRQL being impaired to a greater
degree in patients with a greater symptom burden
[20-26]. The findings of the present study are therefore
in agreement with the latter observations and the results
of a US study [5], which found similar impairment of
HRQL on the EQ-5D and SF-36v2 scales in North
American patients with a partial response to optimized
PPI therapy, as well as a similar relationship between the
severity and frequency of symptoms and the level of
impairment of HRQL.
This study population showed evidence of impaired
work productivity on the WPAI-GERD scale, with
increased absenteeism and presenteeism resulting in
considerable indirect costs. Impaired work-related prod-
uctivity has been observed in patients with GERD in
other studies [26-28], with the studies by Gisbert et al.
and Ekesbo et al. both being examples of studies
assessing productivity loss using the WPAI-GERD scale
in a European population. Both HRQL and impairment
of productivity was shown to be higher in those patientswith greater GERD symptom load in the present study,
results that are consistent with those of the REMAIN
US study [5].
The relationships between symptom load, measured
by the validated RESQ-7, and the WPAI-GERD and EQ-
5D questionnaires lends indirect support to the con-
struct validity of these instruments in this study popula-
tion, as the severity and frequency of GERD symptoms
measured by the RESQ-7 appears to have some predict-
ive value for the degree of impairment of HRQL and
work-related productivity. However, it should be noted
that this study was not designed to test the construct
validity of these scales.
Though the current patient population continued to ex-
perience frequent and severe symptoms of GERD despite
receiving optimized treatment with a PPI with or without
adjunctive therapy with other GERD treatments, only a
low proportion of patients were observed to change treat-
ment categories over the course of the study. Based on
these data, it appears that there is currently no clear treat-
ment alternative to continuing PPI therapy in patients
with partially responsive GERD. While the possibility of
incorrect diagnosis has to be considered, it is important to
note that participating patients had been previously
diagnosed with GERD (at least 6 months previously,
according to medical records) and all had been receiving
optimized PPI therapy according to physician’s judgement.
With regard to GERD diagnosis, we adopted the specified
timeframe of patients having been diagnosed >6 months
beforehand in order to help to confirm the diagnosis in
terms of duration. Although imperfect, this duration con-
straint helped to avoid inclusion of patients with a less
well established diagnosis or very intermittent forms
of GERD. In addition, two thirds of patients had
endoscopically proven GERD, which is a higher rate
than would usually be expected for such patients, and
symptoms were confirmed by use of a validated ques-
tionnaire (RESQ-7).
This study has a number of strengths, including the
large sample size and the use of established patient-
reported outcome measures to evaluate HRQL and
productivity. Use of a pragmatic definition of partial re-
sponse – persistent GERD symptoms despite optimized
PPI therapy, according to the physician’s judgement –
can also be considered a study strength as it helped to
ensure that the study mirrored routine practice. In this
regard it is important to consider that numerous
guidelines have attempted to define partial response.
However, we deliberately avoided proving physicians
with clinical training on the management of GERD or
related guidelines, in order to not interfere with their
routine management of patients with GERD and, in
turn, to obtain real-world data. Factors limiting the study
include the use of patient recall periods of up to
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the potential impact of memory decay was partly over-
come by providing patients with memory aids (diaries)
in which they were encouraged to document use of
medical care and medications for GERD between phys-
ician visits. The measurement of symptoms using a
7-day recall rather than daily measurement may also be
a study limitation, as well as the substantial amount of
missing data such as medication dosages and treatment
dates. In addition, the discrepancy between the number
of office visits recorded by physicians compared with the
number reported by patients highlights the limitations of
collecting data from medical records and patient recall.
The methods used to calculate costs were also subject to
several limitations, including the effects of the unit costs
on cost-of-illness calculations (which may be subject to
variability), the extrapolation of WPAI-GERD data over
7 days to a 3- to 6-month period to estimate productiv-
ity losses and the subjective method of measuring work
productivity.
Conclusions
There is a high symptom load (in terms of frequency and/
or severity) and, in turn, substantial impairment of HRQL
and work productivity and high disease-related costs
among patients in France with persistent symptoms of
GERD despite PPI therapy. Such findings highlight the re-
quirement for new treatment options to meet the unmet
need of such patients. In the meantime, physicians are
encouraged to explore not only the possibility that PPI
treatment is not optimized (even if they believe it to be)
but also the likelihood of incorrect diagnosis and/or the
potential benefits of adjunctive therapies.
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